MA29946B1 - Nouvelles compositions ameliorees pour la therapie du cancer - Google Patents

Nouvelles compositions ameliorees pour la therapie du cancer

Info

Publication number
MA29946B1
MA29946B1 MA30925A MA30925A MA29946B1 MA 29946 B1 MA29946 B1 MA 29946B1 MA 30925 A MA30925 A MA 30925A MA 30925 A MA30925 A MA 30925A MA 29946 B1 MA29946 B1 MA 29946B1
Authority
MA
Morocco
Prior art keywords
methods
improved compositions
cancer therapy
new improved
composition
Prior art date
Application number
MA30925A
Other languages
English (en)
French (fr)
Inventor
Amarjit Singh
Sarabjit Singh
Ajay K Gupta
Mangesh M Kulkarni
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA29946B1 publication Critical patent/MA29946B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA30925A 2005-10-21 2008-05-15 Nouvelles compositions ameliorees pour la therapie du cancer MA29946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1327MU2005 2005-10-21
IN1081MU2006 2006-07-10

Publications (1)

Publication Number Publication Date
MA29946B1 true MA29946B1 (fr) 2008-11-03

Family

ID=38163340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30925A MA29946B1 (fr) 2005-10-21 2008-05-15 Nouvelles compositions ameliorees pour la therapie du cancer

Country Status (13)

Country Link
US (1) US20100166872A1 (enExample)
EP (1) EP1962906A4 (enExample)
JP (1) JP2009512682A (enExample)
AR (1) AR058130A1 (enExample)
AU (1) AU2006324872B2 (enExample)
BR (1) BRPI0617663A2 (enExample)
CA (1) CA2626016A1 (enExample)
CR (1) CR9989A (enExample)
EA (1) EA015781B1 (enExample)
IL (1) IL190882A0 (enExample)
MA (1) MA29946B1 (enExample)
RS (1) RS20080167A (enExample)
WO (1) WO2007069272A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2231144B1 (en) * 2007-12-24 2014-07-02 Sun Pharma Advanced Research Company Limited Nanodispersion
US8865222B2 (en) 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
EP2252266A1 (en) 2008-02-11 2010-11-24 Yissum Research Development Company of the Hebrew University of Jerusalem Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
EP2252269A1 (en) * 2008-02-11 2010-11-24 Technion Research and Development Foundation, Ltd. Casein particles encapsulating therapeutically active agents and uses thereof
GB0818747D0 (en) 2008-10-13 2008-11-19 Univ Nottingham Biocompatible responsive materials
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
EP2442805A4 (en) 2009-06-19 2012-11-21 Sun Pharma Advanced Res Co Ltd NANODISPERSION OF A MEDICINE AND METHOD FOR PREPARING THE SAME
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
CA2774669C (en) * 2009-09-21 2017-12-19 Jw Pharmaceutical Corporation Oxaliplatin nanoparticles and method for preparing same
AU2011248449B2 (en) 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2011151722A2 (en) * 2010-06-01 2011-12-08 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
EP2645991B1 (en) 2010-12-02 2020-02-12 GreenMark Biomedical Inc. Aptamer bioconjugate drug delivery device
ES2629187T3 (es) 2011-04-20 2017-08-07 The University Of Sydney Material en forma de partículas y toxina celular para su uso en el tratamiento de un tumor sólido
US9364433B2 (en) 2011-04-28 2016-06-14 Borje S. Andersson Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
PL3046584T3 (pl) 2013-09-16 2017-11-30 Astrazeneca Ab Terapeutyczne polimeryczne nanocząstki i sposoby ich wytwarzania i stosowania
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом
HRP20251032T1 (hr) 2015-02-01 2025-10-24 Quetzal Therapeutics, Llc Liofilizirani pripravci s visokim površinskim područjem koji sadrže arsen za oralnu primjenu kod pacijenata
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
CN106137969B (zh) 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
WO2018200393A1 (en) * 2017-04-24 2018-11-01 Zy Therapeutics Inc. Pharmaceutical composition for in vivo delivery, method of preparation of a substantially waterinsoluble pharmacologically active agent
WO2019028457A2 (en) * 2017-08-04 2019-02-07 University Of Houston System FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE
EP3773751A4 (en) 2018-03-28 2021-12-01 GreenMark Biomedical Inc. PHOSPHATE CROSS-LINKED STARCH NANOPARTICLE AND DENTAL TREATMENTS
AU2019312592B2 (en) 2018-07-31 2025-06-26 Microbion Corporation Bismuth-thiol compositions and methods for treating wounds
CA3107760A1 (en) 2018-07-31 2020-02-06 Microbion Corporation Bismuth-thiol compositions and methods of use
FR3087650B1 (fr) * 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
CN114767879A (zh) * 2022-06-02 2022-07-22 平顶山学院 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
NZ502500A (en) * 1997-06-27 2002-03-28 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU784416B2 (en) * 1999-05-21 2006-03-30 Abraxis Bioscience, Llc Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO2001049268A1 (en) * 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
KR20110079741A (ko) * 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법

Also Published As

Publication number Publication date
CR9989A (es) 2008-07-18
US20100166872A1 (en) 2010-07-01
WO2007069272A3 (en) 2007-08-23
EP1962906A4 (en) 2009-11-18
EP1962906A2 (en) 2008-09-03
EA015781B1 (ru) 2011-12-30
AU2006324872A1 (en) 2007-06-21
CA2626016A1 (en) 2007-06-21
WO2007069272A2 (en) 2007-06-21
RS20080167A (sr) 2009-07-15
AR058130A1 (es) 2008-01-23
JP2009512682A (ja) 2009-03-26
BRPI0617663A2 (pt) 2011-08-02
IL190882A0 (en) 2008-11-03
EA200801132A1 (ru) 2009-02-27
AU2006324872B2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
MA29946B1 (fr) Nouvelles compositions ameliorees pour la therapie du cancer
WO2009120697A4 (en) Method and compositions for treatment of cancer
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
HUP0400203A2 (hu) Epotilon analógok és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére alkalmas gyógyszerkészítmény előállítására
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
FI952248A7 (fi) Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
WO2007139930A3 (en) Drug combinations with substituted diaryl ureas for the treatment of cancer
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA34308B1 (fr) Triazolopyridines substituées
WO2008105852A3 (en) Mucoadhesive nanoparticles for cancer treatment
MA30325B1 (fr) Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
MA30410B1 (fr) Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique.
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
NO994408L (no) Dolastatin-15 derivater i kombinasjon med taxaner
FR3059236B1 (fr) Extraits de plantes du genre tagetes et leurs utilisations
PE20061090A1 (es) Preparaciones de taxanos sustituidos con esteres de ciclopropilo en c10
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
RU2010121882A (ru) Новая композиция для лечения побочных эффектов противораковой терапии